Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TV-202
- Development stage
- Preclinical
- Lead developer
- TheraVac Biologics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
TV-202 is a preclinical-stage virus-like particle (VLP)-based vaccine being developed by TheraVac Biologics for the treatment of neurodegenerative and inflammatory conditions, specifically frontotemporal dementia (FTD) and primary progressive multiple sclerosis (PPMS). The vaccine utilizes TheraVac's VLP platform to display immunogenic peptides that elicit an active immune response against the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) and ASC (apoptosis-associated speck-like protein containing a CARD) components of the inflammasome. By targeting these proteins, TV-202 aims to reduce or neutralize the activity of the NLRP3 inflammasome, thereby mitigating chronic inflammation and the progression of diseases associated with misfolded protein aggregates. The platform is designed to elicit strong immune responses without the requirement for pro-inflammatory adjuvants.
Beyond the preview
Go deeper on TV-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TV-202.